Derbyshire Medicines Management and Clinical Policies
NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor). Lapatinib & trastuzumab – not recommended with an aromatase inhibitor for post-menopausal women with HER2 and hormone receptor positive metastatic breast cancer.
(This drug can be funded through the cancer drug fund - seek advice from the oncologist/haematologist)
